Live feed07:00:00·86dPRReleasevia QuantisnowOKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal PainByQuantisnow·Wall Street's wire, on your screen.OKYO· OKYO Pharma LimitedHealth Care
